A hand pouring an Ozzi watermelon drink stick into a water bottle beside the Ozzi pouch and a canvas tote bag

How to Stop Wegovy: A Practical Taper and Transition Guide

By Brandon, founder of Ozzi · Published August 23, 2026

TL;DR: There's no medically required taper for Wegovy, but stepping down the dose ladder gives you a runway to build habits while appetite is still partly suppressed. That runway is the whole game. Here's how to structure it, what to have in place first, and what to expect week by week.
To stop Wegovy, work with your prescriber to step down through the dose ladder rather than quitting at 2.4mg. Semaglutide clears over about five weeks. Use that window to establish resistance training, a protein target, and daily fiber and butyrate support before appetite fully returns.

Key takeaways

  • No safety taper required, but stepping down buys time
  • Build habits while appetite is still suppressed
  • Resistance training protects lean mass and blunts regain
  • Semaglutide clears in roughly five weeks
  • Evening cravings usually return first

Do you need to taper off Wegovy?

Not for safety. Semaglutide isn't habit-forming and there's no dangerous rebound that requires a medical wean. You could stop at 2.4mg tomorrow with no acute risk.

The honest state of the evidence: a 2026 review in Diabetes, Obesity & Metabolism, drawing on randomized withdrawal trials and real-world cohorts covering more than 289,000 patients, explicitly notes the absence of validated tapering strategies. Nobody has run the trial that proves a specific step-down schedule beats stopping cold.

What that review does recommend is a structured, multidisciplinary transition rather than treating the last dose as an endpoint. It calls discontinuation "a high-risk clinical transition."

So the argument for stepping down is a practical one. A gradual reduction gives you weeks of partial appetite suppression to build the habits you'll need at zero. Going from full suppression to nothing in one week means learning to eat at maintenance at the exact moment hunger peaks.

What does a step-down schedule look like?

Wegovy titrates up through 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg. Coming down usually means walking that ladder in reverse.

A common structure prescribers use looks like this. Your prescriber sets your actual schedule, and this is only here so you know what to ask about.

Phase Typical duration What you're building
2.4mg to 1.7mg 4 weeks Resistance training routine. Protein target locked in.
1.7mg to 1.0mg 4 weeks Daily fiber and butyrate habit. Evening routine that isn't food.
1.0mg to 0.5mg 4 weeks Practice eating at maintenance with mild appetite return.
0.5mg to 0.25mg 4 weeks Weekly weigh-ins. Set your restart threshold with your doctor.
Off Ongoing Everything above is now automatic. That was the point.

Roughly four months. That feels slow when you're motivated to be done. It's the difference between arriving at zero with systems running and arriving there improvising.

A taper buys you runway. Use it to build the habits that have to carry you afterward.

Why is protecting muscle the top priority?

Because it determines what the regain looks like, and most people find out too late.

A review in Diabetes Care examined body composition on incretin therapies. GLP-1 and dual agonist drugs drive large weight loss, and roughly 10% of it, around 6kg, is lean mass. The authors compare that to a decade or more of normal aging.

Here's why it compounds. Muscle burns calories at rest. Lose 6kg of it and your maintenance calories drop. If weight then returns as fat, you end up at a similar scale number with less muscle and a lower metabolic rate than when you started, which makes the next attempt harder.

The same review points at the fix: supervised resistance training beyond 10 weeks produced roughly 3kg of lean mass gain and 25% strength gain. The authors propose that retaining lean mass during treatment could blunt fat regain after stopping.

Two sessions a week covering the major movement patterns is enough to change this outcome. Start it during the taper, while recovery is still supported by adequate intake.

Natural GLP-1 support

Ozzi Crave Crusher

Built for exactly this window. Ozzi supports your body's own GLP-1 production rather than replacing it: 8g allulose, 500mg BIOMEnd L-lysine butyrate, 500mg glucomannan, 500mg chicory root inulin, plus African mango and chromium. No caffeine, no stimulants, vegan. Start it during the taper so it's a habit by the time you're off.

"I cannot say enough about this product. I was on a GLP-1 for 2 years and benefited most from the food noise reduction. I chose to get off of it due to its high cost. I have tried absolutely everything on the market and nothing, absolutely nothing has had the same effect until I came across Ozzi. I am a customer for life!"Noralyn, verified customer

Try Crave Crusher

14-Day Ozzi Challenge: take it for 14 straight days. If your cravings and food noise aren't quieter, we'll refund your first bag.

What happens to your appetite as the dose drops?

It returns in stages, which is the point of stepping down.

Expect food noise to get louder at each reduction, then partially settle over one to two weeks as you adjust. Evenings go first. Our post-purchase survey data has around 45% of customers naming after-dinner snacking as their main problem, and that pattern shows up in tapers too.

There's a second layer worth understanding, because it explains why appetite doesn't just return to your pre-Wegovy baseline.

Weight loss itself resets your appetite hormones. Sumithran and colleagues, writing in the New England Journal of Medicine, tracked nine hormones through a weight-loss program and out to 62 weeks. After weight loss, ghrelin rose while leptin, peptide YY and cholecystokinin fell. A year later, those changes were still present, and measured hunger was still significantly above baseline.

So you're stepping down into a hungrier hormonal setting than you started in. Your cravings aren't really a willpower problem, they're a hormone problem, and knowing that changes how you plan for it.

How do you support your own GLP-1 production?

Your intestinal L-cells make GLP-1 in response to what reaches your gut. That system is intact and responsive. Wegovy was amplifying the signal, not building the machinery.

Butyrate. A postbiotic your gut bacteria produce by fermenting fiber. It's the primary fuel for the cells lining your colon and supports gut barrier function. In mouse and cell studies, butyrate stimulates the L-cells that secrete GLP-1, which is the proposed mechanism driving interest in it. Human confirmation is pending.

The human data we do have is on delivery, and it's good. A 2025 randomized crossover trial dose-matched three butyrate forms in healthy adults and measured serum butyrate by GC-MS. L-lysine butyrate, the BIOMEnd form Ozzi uses, reached peak serum butyrate at 20 minutes, roughly 5 times tributyrin's peak, and rated most palatable in organoleptic testing.

Chicory root inulin. Prebiotic fiber that feeds the bacteria producing butyrate in your colon. Supplying butyrate directly and feeding your own production is the more complete approach.

Glucomannan. Viscous konjac fiber that absorbs water and expands in the stomach for physical fullness. A network meta-analysis of 111 randomized trials in Pharmacological Research found a mean weight difference of 1.36kg versus control.

Allulose. A rare sugar that tastes like sugar at roughly a tenth of the calories, without sugar's glucose and insulin response. It handles the sweet side of cravings.

Chromium. An essential trace mineral with a well-established role in insulin signaling and glucose metabolism.

What if you're stopping because of cost?

You're in the majority, and it's worth exhausting the alternatives first.

Real-world data in JAMA Network Open covering 125,474 US adults found 64.8% of people without type 2 diabetes discontinued within one year. Higher income was associated with staying on treatment, which tells you plainly what's driving most exits.

Before you stop over price, ask your prescriber about manufacturer savings programs, appealing a coverage denial, whether a lower maintenance dose is reasonable for you, and whether a different agent has better coverage under your plan.

One note if you're on Wegovy for liver disease rather than weight: the Wegovy formulation received accelerated FDA approval in August 2025 for MASH with moderate-to-advanced fibrosis. If that's your indication, stopping is a materially different decision and needs your hepatologist involved.

Nearly two-thirds of people without diabetes stop within a year. You're not failing at this. You're the norm.

Start it during the taper, not after

One stick in 16oz of cold water, once a day. Supports natural GLP-1 production, adds viscous and prebiotic fiber, and takes the edge off sweet cravings with allulose instead of sugar.

"I've been using Ozzi for just a few days now but it definitely curbs my hunger. It's so much more pleasant than the feeling I got from the GLP-1 meds. No nausea at all. And it tastes great too!"Dan, verified customer

Try Crave Crusher

Join 10,000+ Ozzi customers. 14-Day Ozzi Challenge: take it for 14 straight days. If your cravings and food noise aren't quieter, we'll refund your first bag.

Frequently asked questions

How do you stop Wegovy safely?

Talk to your prescriber and agree a plan. There's no safety requirement to taper, but stepping down the dose ladder over roughly four months gives you time to build habits while appetite is still partly suppressed.

How long does Wegovy stay in your system?

Semaglutide's half-life is about one week, so substantial clearance takes roughly five weeks after the last injection.

Will I gain the weight back after stopping Wegovy?

Most people regain a significant portion. The STEP 1 trial extension found participants regained about two-thirds of lost weight within a year. Pooled data puts the range at 60% to 90%. Protecting muscle and keeping daily habits changes where you land in that range.

Is stopping Wegovy cold turkey dangerous?

Not medically dangerous for most people. The risk is behavioral: appetite returns fully and quickly with no habit scaffolding in place. Anyone with type 2 diabetes needs glucose monitoring through the transition.

What should I eat after stopping Wegovy?

Protein at every meal to defend muscle, viscous fiber for satiety, and prebiotic fiber to support butyrate production in your gut. Consistency matters more than perfection.

When will my appetite come back?

Usually 2 to 4 weeks after your final dose, or within 1 to 2 weeks of each dose reduction if you're stepping down. Evenings are typically the first place you notice it.

Can I take Ozzi while tapering off Wegovy?

Many customers do, and starting during the taper is the better move because the habit is established before appetite fully returns. Check with your prescriber first.

Will the nausea stop?

Yes. Gastrointestinal effects were the most common adverse events across the STEP program, and they resolve as the drug clears and gastric emptying returns to normal speed.

Should I restart if I regain?

That's a prescriber conversation, and a common one. In the JAMA Network Open cohort, about 36% of non-diabetic patients reinitiated within a year, with weight regain the strongest predictor. Deciding your threshold in advance is easier than deciding it in the moment.

Related reading

About the author

Brandon is the founder of Ozzi. He built the formula after months of reading the literature on why cravings intensify after weight loss, and he answers ingredient questions personally on Reddit and in the comments on Ozzi's ads.

References

  1. Shah E, et al. Clinical management of weight regain and cardiometabolic consequences after discontinuation of GLP-1 receptor agonists. Diabetes Obes Metab. 2026;28(6):4546-4558. https://doi.org/10.1111/dom.70713
  2. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
  3. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. https://doi.org/10.1056/NEJMoa1105816
  4. Locatelli JC, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47(10):1718-1730. https://doi.org/10.2337/dci23-0100
  5. Rodriguez PJ, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. https://doi.org/10.1001/jamanetworkopen.2024.57349
  6. Bansal MB, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025;83(5):1326-1340. https://doi.org/10.1097/HEP.0000000000001608
  7. Shahinfar H, et al. Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: a network meta-analysis of 111 randomized clinical trials. Pharmacol Res. 2023;196:106944. https://doi.org/10.1016/j.phrs.2023.106944
  8. La Monica MB, et al. Comparative pharmacokinetics of three butyrate supplements in healthy adults. J Exerc Nutr. 2025;8(1):4. NCT06700785.

This article is for general information and is not medical advice. Ozzi is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Never start, stop or change a prescription medication without talking to your healthcare provider.

Back to blog